PROTACs work differently from conventional drugs that merely inhibit a protein’s activity. A typical PROTAC is a bifunctional molecule with one end that binds to a disease-associated protein and another that recruits an E3 ubiquitin ligase, part of the cell’s protein-disposal machinery. By bringing the target protein and the ligase into close proximity, the PROTAC causes the target to be tagged with ubiquitin molecules. The proteasome, a large intracellular complex that degrades ubiquitinated proteins, then dismantles the marked protein. Because a PROTAC can act catalytically—detaching after the target is destroyed and potentially engaging another copy—it may eliminate proteins rather than temporarily blocking them. That promise has attracted intense interest in oncology, where many disease-driving proteins have proved difficult to inhibit with traditional small molecules.

The same molecular features that make PROTACs powerful can also make them difficult to deliver. Many are relatively large and chemically complex, occupying what medicinal chemists call “beyond rule-of-five” space. Their size and polarity can reduce passive diffusion through the lipid bilayer of a cell membrane, while their hydrophobicity can limit water solubility and cause unfavorable distribution in the body. A PROTAC circulating in the bloodstream must reach a tumor, cross or enter cancer cells, escape destructive clearance pathways and arrive in the correct intracellular compartment before it can assemble the molecular interactions needed for protein degradation. Poor membrane permeability and inadequate tumor distribution therefore represent major barriers between promising laboratory chemistry and a practical medicine.

The researchers addressed these problems by attaching a hydrophobic PROTAC called MZ1 to a hydrophilic affibody known as Z_HER2:342. MZ1 is designed to degrade bromodomain-containing protein 4, or BRD4, while the affibody is an engineered affinity protein that recognizes human epidermal growth factor receptor 2, commonly called HER2. Affibodies are small, engineered binding proteins derived from an alpha-helical bacterial receptor domain. Unlike full-size antibodies, they are compact and can be produced and chemically modified as defined molecules. Z_HER2:342 supplies the targeting function, while MZ1 supplies the protein-degradation function. The two components were connected by a linker containing a disulfide bond, creating an amphiphilic conjugate with one water-compatible region and one water-avoiding region.

When placed in water, the conjugates spontaneously organized into nanoparticles, a process known as self-assembly. Amphiphilic molecules can form nanoscale structures because their hydrophilic and hydrophobic sections seek different environments: the water-compatible affibody portions remain exposed to the surrounding liquid, while the hydrophobic MZ1 portions cluster away from it. This arrangement allows the drug molecules to be carried in a compact, water-dispersible form without requiring a separate polymeric carrier or lipid shell. The resulting formulation, called the Z_HER2:342-MZ1 affibody-PROTAC conjugate nanomedicine, was intended to solve two delivery problems at once—keeping MZ1 dispersed in the bloodstream and displaying the HER2-binding affibody on the nanoparticle surface.

The targeting mechanism depends on the abundance of HER2 on the surface of selected cancer cells. HER2 is a receptor tyrosine kinase involved in signaling pathways that regulate proliferation, survival and differentiation. In some breast, ovarian and other cancers, the receptor is produced at unusually high levels, creating a molecular marker that can distinguish malignant cells from many normal tissues. According to the study, the nanoparticles used HER2 receptor-mediated endocytosis to gain entry into cancer cells. In this process, binding at the cell surface triggers the membrane to fold inward and form an intracellular vesicle containing the bound material. The researchers reported effective accumulation and internalization of the conjugate in HER2-positive cancer cells in vitro, consistent with the idea that affibody-mediated recognition improved delivery beyond what free MZ1 could achieve.

The disulfide linker was designed to respond to the reducing conditions inside cells. Glutathione, or GSH, is a major intracellular antioxidant and is generally present at higher concentrations within cells than in the extracellular space or bloodstream. Its thiol group can participate in reduction reactions that cleave disulfide bonds. In the proposed system, intracellular GSH breaks the linker connecting the affibody and MZ1, releasing the PROTAC after the nanoparticle has been internalized. This is a form of chemically triggered release: the carrier remains comparatively stable during circulation but becomes labile in a cellular environment rich in reducing agents. Once liberated, MZ1 can interact with BRD4 and recruit the ubiquitin-proteasome system, converting the delivery event into targeted destruction of an intracellular protein.

BRD4 belongs to the bromodomain and extraterminal, or BET, family of epigenetic reader proteins. Rather than acting as a conventional DNA-binding transcription factor, BRD4 recognizes acetylated lysine residues on histones and other proteins, helping organize transcriptional machinery at active genes. It is particularly associated with regulatory regions such as enhancers and super-enhancers, where it can support expression programs that sustain cancer-cell proliferation and survival. Degrading BRD4 can therefore disrupt multiple transcriptional networks at once. The study reported that the released MZ1 produced BRD4 deficiency and subsequently induced apoptosis, the regulated form of cell death. This mechanism is distinct from simply slowing an enzyme: it removes an entire protein platform that cancer cells may depend on for maintaining gene expression.

The researchers then evaluated the conjugate in vivo after administration through the tail vein in mice carrying HER2-positive SKOV-3 tumors. Intravenous delivery places the formulation directly into the circulation, where its size, surface properties and targeting ligand influence how long it remains in the blood and where it accumulates. The study reported outstanding tumor-specific targeting, increased drug accumulation, enhanced BRD4 degradation and improved antitumor efficacy compared with relevant controls. These findings suggest that the nanoparticles retained their targeting function in the complex environment of an animal and that sufficient MZ1 reached tumor cells to engage its intracellular mechanism. The results also support the value of combining receptor-mediated uptake with a redox-sensitive release step, rather than relying solely on passive nanoparticle accumulation in tumors.

The work does not yet establish whether the platform is safe or effective in people. Mouse tumors do not reproduce the full biological diversity of human cancers, and HER2 expression can vary between tumors and even between cells within the same tumor. The distribution, metabolism and elimination of affibody-based nanoparticles will also need to be characterized in detail, as will possible immune responses, off-target BRD4 degradation and toxicity in healthy tissues. In addition, a clinical formulation would have to meet demanding requirements for manufacturing consistency, stability and dose control. Even so, the study points toward a versatile strategy: a compact targeting protein, a cleavable chemical linker and a self-assembling PROTAC payload are integrated into one molecule that builds its own nanomedicine. If the design can be optimized and validated in more advanced models, it could help turn targeted protein degradation from a promising intracellular concept into a more precise way of delivering cancer therapy.

The cornerstone of modern oncology is the capacity to attack malignant cells selectively, minimizing collateral damage that causes debilitating side effects. Antibody–drug conjugates (ADCs), which marry the targeting specificity of monoclonal antibodies with cytotoxic drugs, have already marked a significant advance by directly homing in on cancer cells. Nevertheless, their bulky structure limits how deeply they penetrate tumors and caps the amount of drug payload they can deliver, leaving room for more efficient and flexible solutions.

Addressing these limitations, the UNIGE team has innovated with DNA-based components, which are considerably smaller than traditional antibodies. Their diminutive size facilitates enhanced mobility through the dense and often impenetrable tumor microenvironment. This innovation enables DNA strands to permeate tumor tissue more effectively, circumventing a key obstacle in the delivery of therapeutics to solid tumors.

Central to this technology is a modular design where separate DNA strands carry distinct functionalities: two different cancer-targeting binder molecules and a highly cytotoxic payload. This modularity allows for a complex assembly process at the tumor site, driven by the presence of specific molecular markers unique to cancer cells. When two particular cancer biomarkers interact with their corresponding DNA-linked binders, the separate DNA fragments initiate a hybridization chain reaction, self-assembling into a larger structure that delivers an amplified dose of the drug precisely where needed.

This approach mirrors the principle of two-factor authentication in cybersecurity, where secure access requires two separate keys. Similarly, the drug delivery system activates only upon simultaneous recognition of both cancer markers. This “AND” logic gate mechanism ensures exceptional specificity, drastically reducing the risk of activating the drug in healthy tissue, where one or both markers are absent. The drug payload remains inert in the absence of this exact combination, thus sparing healthy cells and mitigating systemic toxicity.

Laboratory experiments have shown the system’s extraordinary precision. Cancerous cells bearing the two defined protein markers were selectively identified and targeted, resulting in the effective destruction of these malignant cells without affecting neighboring healthy cells. This precision heralds the potential for therapies that are not only more effective but also substantially safer for patients, alleviating the often debilitating side effects of conventional chemotherapy.

Beyond single-drug administration, the research demonstrates the capability to integrate multiple therapeutics within one treatment regime. By combining different cytotoxic agents in a single DNA-mediated delivery platform, this approach provides a strategic advantage in combating drug resistance, one of the most pervasive challenges in oncology. Tumors that evolve resistance to one class of drugs may be effectively targeted by a multipronged assault, thereby enhancing long-term treatment efficacy.

Professor Nicolas Winssinger, the study’s senior author, highlights the novel concept underlying this system: “What’s transformative here is that the drug molecule itself can ‘compute’ biological signals and respond intelligently.” Unlike traditional therapeutics passively delivered through the bloodstream, this new paradigm represents a shift towards autonomous, self-regulating medicines capable of logic-based decision-making at the molecular level.

This intelligent system employs fundamental logic operations analogous to those underpinning conventional computers—“AND,” “OR,” and “NOT” gates—but implemented through molecular interactions. The current proof-of-concept utilizes an “AND” gate, activating the drug only in the presence of two distinct biomarkers. This molecular computation not only enhances drug selectivity but also opens the doorway to future medicines layered with complex logic gates, capable of nuanced responses to the biochemical environment of each patient.

Looking forward, the integration of additional logic gates could give rise to programmable drugs with unparalleled sophistication, adjusting therapeutic delivery dynamically based on comprehensive molecular cues. Such adaptability could signify a watershed moment in personalized medicine, enabling treatments tailored at an unprecedented level to an individual’s unique disease signature and physiological state, all while minimizing side effects and improving patient outcomes.

These advances are not intended to replace medical professionals but to augment clinical decision-making by providing highly controllable, targeted therapeutics. As this technology matures, it holds the potential to transform the oncology landscape, making cancer therapies more precise, efficient, and patient-friendly. Moreover, the principles demonstrated here may extend beyond cancer, enabling the development of smart therapeutics for a broad spectrum of diseases where targeted drug delivery is critical.

Supported by the Swiss National Science Foundation and building on foundational work from the NCCR Chemical Biology program, the UNIGE research embodies a pioneering approach at the intersection of chemistry, biology, and information technology. Published in Nature Biotechnology, the study exemplifies the potential of molecular computing in medicine, laying groundwork for a future where treatments act with computational intelligence, internalizing and interpreting biological information to guide their action.

As the field progresses, this molecular logic-gated drug delivery system may catalyze a paradigm shift, ushering in an era where “smart” medicines not only fight disease more effectively but also adapt in real time to the complex, evolving biology of the human body. The promise of programmable, responsive therapeutics stands as a beacon of hope for patients worldwide, signaling a future where cancer and other fatal diseases can be treated with precision, potency, and personalized care.

Subject of Research:
DNA-based logic-gated drug delivery systems targeting cancer cells

Article Title:
DNA–drug conjugates enable logic-gated drug delivery amplified by hybridization chain reactions

News Publication Date:
27-Mar-2026

Web References:
http://dx.doi.org/10.1038/s41587-026-03044-0

Keywords:
Cancer targeting, DNA–drug conjugates, hybridization chain reaction, logic-gated drug delivery, molecular computing, targeted therapy, synthetic DNA, personalized medicine, tumor specificity, drug resistance, oncology, smart therapeutics